Pluri Inc

For the period ended Dec 31, 2024. Filed Feb 11, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2024 · Filed Feb 11, 2025

PLUR$1.12-5.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Interim Condensed Consolidated Statements of Operations (Unaudited)

U.S. Dollars in thousands (except share and per share data)

Six months ended December 31 · Three months ended December 31,
	Note	2024	2023	2024	2023
Revenues		$511	$159	$185	$105
Cost of revenues		(200)	-	(74)	-
Gross profit		311	159	111	105
Operating expenses:
Research and development expenses		$(6,562)	$(6,704)	$(3,170)	$(3,338)
Less: participation by the National Institute of Allergy and Infectious Diseases, or NIAID, the Israeli Innovation Authority, or IIA, Horizon Europe and other parties		748	747	245	374
Research and development expenses, net		(5,814)	(5,957)	(2,925)	(2,964)
General and administrative expenses		(4,652)	(4,792)	(2,143)	(2,354)
Operating loss		(10,155)	(10,590)	(4,957)	(5,213)
Other financial income, net	6	1,437	928	2,058	435
Interest expenses		(428)	(430)	(211)	(216)
Total financial income, net		1,009	498	1,847	219
Net loss		$(9,146)	$(10,092)	$(3,110)	$(4,994)
Net loss attributed to non-controlling interest		$(308)	$(226)	$(154)	$(89)
Net loss attributed to shareholders		$(8,838)	$(9,866)	$(2,956)	$(4,905)
Loss per share:
Basic and diluted net loss per share		$(1.61)	$(1.92)	$(0.53)	$(0.96)
Weighted average number of shares used in computing basic and diluted net loss per share (**)		5,505,915	5,178,555	5,552,931	5,190,853

(**)	See note 5(1) regarding reverse share split

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.